# US 2025/0375541 A1 · Radiopharmaceutical composition and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375541 A1
- Document ID: US20250375541A1
- Status: Published application
- Kind: A1
- Application number: 19/212,232
- Filed: 2025-05-19
- Published: 2025-12-11
- Earliest claimed: 2024-06-05
- Assignees: Ariceum Therapeutics GmbH
- Applicants: Ariceum Therapeutics GmbH
- Inventors: Manuel STURZBECHER-HÖHNE; Dennis MEWIS; Marion HUBER
- Web page: https://patentgrep.com/patent/US20250375541A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/121: {Solutions, i.e. homogeneous liquid formulation}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a liquid radiopharmaceutical composition comprising a radiopharmaceutical compound according to Formula I or a pharmaceutically acceptable salt thereof; and a buffer, wherein the buffer provides the radiopharmaceutical composition with a pH of about 7.0 to about 8.9. The present invention also relates to a pre-composition, starter composition, and kit, which can find use in preparing the liquid radiopharmaceutical composition, as well as to methods of preparing the liquid radiopharmaceutical composition, and medical uses of the liquid radiopharmaceutical composition.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A method of preparing a liquid radiopharmaceutical composition comprising a radiopharmaceutical compound according to Formula I
or a pharmaceutically acceptable salt thereof,
the method comprising:
providing a liquid radiopharmaceutical pre-composition comprising:
(i) a precursor compound according to Formula II
or a pharmaceutically acceptable salt thereof;
(ii) a buffer, wherein the buffer provides the liquid radiopharmaceutical pre-composition with a pH of about 7.0 to about 8.9; and
(iii) a [225Ac]Ac3+ salt;
heating the liquid radiopharmaceutical pre-composition to generate a labelled composition;
cooling the labelled composition; and
diluting the labelled composition with a formulation solution to generate the liquid radiopharmaceutical composition.

### Claim 37 (depends on 36)

The method of claim 36, wherein the formulation solution comprises a formulation buffer that provides the liquid radiopharmaceutical composition with a pH of about 7.0 to about 8.9.

### Claim 38 (depends on 36)

The method of claim 36, wherein the heating of the liquid radiopharmaceutical pre-composition is at a temperature of at least about 75° C.

### Claim 39 (depends on 36)

The method of claim 36, wherein the heating of the liquid radiopharmaceutical pre-composition is for at least about 20 minutes.

### Claim 40 (depends on 37)

The method of claim 37, wherein the labelled composition is diluted between 5 times and 100 times with the formulation solution.

### Claim 41 (depends on 37)

The method of claim 37, wherein at least part of cooling the labelled composition occurs on diluting the labelled composition with the formulation solution.

### Claim 42 (depends on 36)

The method of claim 36, wherein the radiopharmaceutical compound is present at a concentration equivalent to about 0.1 MBq/mL to about 0.5 MBq/mL based on the total volume of the liquid radiopharmaceutical composition.

### Claim 43 (depends on 37)

The method of claim 37, wherein the buffer and formulation buffer are present at a combined concentration of between about 1 mM to about 100 mM based on the total volume of the liquid radiopharmaceutical composition.

### Claim 44 (depends on 36)

The method of claim 36, wherein the liquid radiopharmaceutical composition comprises a stabiliser selected from ascorbic acid, gentisic acid, glutathione, methionine, hydroquinone, polyoxyethylene (20) sorbitan monooleate, or structural analogues thereof, or pharmaceutically acceptable salts thereof, or combinations thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the stabiliser is ascorbic acid or a pharmaceutically acceptable ascorbate.

### Claim 46 (depends on 44)

The method of claim 44, wherein the stabiliser is present at a concentration of greater than 350 mM based on the total volume of the liquid radiopharmaceutical composition.

### Claim 47 (depends on 36)

The method of claim 36, wherein the liquid radiopharmaceutical composition retains a radiochemical purity of >91% after 168 hours at ambient temperature.

### Claim 48 (depends on 36)

The method of claim 36, wherein the buffer provides the liquid radiopharmaceutical pre-composition with
(a) a pH of about 7.1 to about 8.9;
(b) a pH of about 7.2 to about 8.8;
(c) a pH of about 7.3 to about 8.7;
(d) a pH of about 7.4 to about 8.6;
(e) a pH of about 7.5 to about 8.5;
(f) a pH of about 7.6 to about 8.4;
(g) a pH of about 7.7 to about 8.3;
(h) a pH of about 7.8 to about 8.2; or
(i) a pH of about 7.9 to about 8.1.

### Claim 49 (depends on 36)

The method of claim 36, wherein the buffer provides the liquid radiopharmaceutical pre-composition with a pH of about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8 or about 7.9.

### Claim 50 (depends on 36)

The method of claim 36, wherein the buffer provides the liquid radiopharmaceutical pre-composition with a pH of about 8.0, about 8.1, about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, about 8.8 or about 8.9.

### Claim 51 (depends on 36)

The method of claim 36, further comprising administering the liquid radiopharmaceutical composition to a subject in need thereof.

### Claim 52 (depends on 37)

The method of claim 37, further comprising administering the liquid radiopharmaceutical composition to a subject in need thereof.

### Claim 53 (depends on 48)

The method of claim 48, further comprising administering the liquid radiopharmaceutical composition to a subject in need thereof.

### Claim 54 (depends on 49)

The method of claim 49, further comprising administering the liquid radiopharmaceutical composition to a subject in need thereof.

### Claim 55 (depends on 50)

The method of claim 50, further comprising administering the liquid radiopharmaceutical composition to a subject in need thereof.

### Claim 56 (depends on 36)

A method of treating of a subject in need thereof, said method comprising:
(a) preparing a liquid radiopharmaceutical composition according to the method of claim 36; and
(b) administering to the subject a therapeutically effective amount of the liquid radiopharmaceutical composition.

### Claim 57 (depends on 37)

A method of treating of a subject in need thereof, said method comprising:
(a) preparing a liquid radiopharmaceutical composition according to the method of claim 37; and
(b) administering to the subject a therapeutically effective amount of the liquid radiopharmaceutical composition.

### Claim 58 (depends on 48)

A method of treating of a subject in need thereof, said method comprising:
(a) preparing a liquid radiopharmaceutical composition according to the method of claim 48; and
(b) administering to the subject a therapeutically effective amount of the liquid radiopharmaceutical composition.

### Claim 59 (depends on 49)

A method of treating of a subject in need thereof, said method comprising:
(a) preparing a liquid radiopharmaceutical composition according to the method of claim 49; and
(b) administering to the subject a therapeutically effective amount of the liquid radiopharmaceutical composition.

### Claim 60 (depends on 50)

A method of treating of a subject in need thereof, said method comprising:
(a) preparing a liquid radiopharmaceutical composition according to the method of claim 50; and
(b) administering to the subject a therapeutically effective amount of the liquid radiopharmaceutical composition.
